CCL

Összesen 3 találat.
#/oldal:
Részletezés:
Rendezés:

1.

001-es BibID:BIBFORM038797
Első szerző:Dougados, Maxime
Cím:Continuous efficacy of etanercept in severe and advanced ankylosing spondylitis : results from a 12-week open-label extension of the SPINE study / Dougados, M., Braun, J., Szanto, S., Combe, B., Geher, P., Leblanc, V., Logeart, I.
Dátum:2012
ISSN:1462-0324
Megjegyzések:OBJECTIVE: To evaluate the longer-term efficacy of etanercept in patients with severe and advanced active AS. METHODS: Seventy-seven patients who completed the randomized, double-blind, placebo-controlled 12-week SPINE study enrolled in a 12-week open-label extension and received s.c. etanercept 50 mg once weekly. The etanercept/etanercept group received a total of 24 weeks treatment with etanercept (n=38); the placebo/etanercept group received placebo during the double-blind study then 12 weeks' etanercept treatment during the open-label extension (n=39). RESULTS: At the end of the open-label extension, BASDAI scores in the etanercept/etanercept group had further decreased beyond reductions observed during the double-blind study [mean (s.d.) change from baseline -37.6 (22.4) at end of extension vs -27.4 (23.8) at end of double-blind study]. Mean (s.d.) BASDAI scores also improved in the placebo/etanercept group once switched to etanercept [-28.6 (24.3) vs -15.0 (20.0)]. Similar trends were observed in BASFI and BASMI scores. In the placebo/etanercept group, total back pain decreased to similar levels achieved in the etanercept group in the double-blind study. Pain levels continued to decrease with longer-term etanercept therapy in the etanercept/etanercept group. CONCLUSION: Despite the improvements in symptoms and inflammatory markers observed shortly after initiation of once-weekly etanercept, there was no notable plateauing effect on patient-reported outcomes. Indeed, signs and symptoms of severe and advanced active AS continued to improve after up to 24 weeks, treatment with etanercept.
Tárgyszavak:Orvostudományok Klinikai orvostudományok idegen nyelvű folyóiratközlemény külföldi lapban
Megjelenés:Rheumatology. - 51 : 9 (2012), p. 1687-1696. -
További szerzők:Braun, Jurgen Szántó Sándor (1968-) (belgyógyász, reumatológus) Combe, Bernard Géher Pál Leblanc, Véronique Logeart, Isabelle
Internet cím:Szerző által megadott URL
DOI
Intézményi repozitóriumban (DEA) tárolt változat
Borító:

2.

001-es BibID:BIBFORM038798
Első szerző:Dougados, Maxime
Cím:Nonsteroidal antiinflammatory drug intake according to the Assessment of SpondyloArthritis International Society Score in clinical trials evaluating tumor necrosis factor blockers : example of etanercept in advanced ankylosing spondylitis / Dougados Maxime, Braun Jurgen, Szanto Sandor, Combe Bernard, Geher Pal, Leblanc Véronique, Logeart Isabelle
Dátum:2012
ISSN:2151-464X
Tárgyszavak:Orvostudományok Klinikai orvostudományok idegen nyelvű folyóiratközlemény külföldi lapban
Megjelenés:Arthritis Care & Research. - 64 : 2 (2012), p. 290-294. -
További szerzők:Braun, Jurgen Szántó Sándor (1968-) (belgyógyász, reumatológus) Combe, Bernard Géher Pál Leblanc, Véronique Logeart, Isabelle
Internet cím:Szerző által megadott URL
DOI
Intézményi repozitóriumban (DEA) tárolt változat
Borító:

3.

001-es BibID:BIBFORM015785
Első szerző:Dougados, Maxime
Cím:Efficacy of etanercept on rheumatic signs and pulmonary function tests in advanced ankylosing spondylitis : results of a randomised double-blind placebo-controlled study (SPINE) / M. Dougados, J. Braun, S. Szanto, B. Combe, M. Elbaz, P. Geher, G. Thabut, V. Leblanc, I. Logeart
Dátum:2011
ISSN:0003-4967
Megjegyzések:OBJECTIVES: /st> Patients with advanced ankylosing spondylitis (AS) experience disability because of reduced spinal mobility and pulmonary function impairment. This placebo-controlled study evaluated the effect of etanercept (ETN) in patients with advanced AS. METHODS: /st> A multicentre randomised double-blind placebo-controlled trial of 12 weeks' duration was performed. Patients had definite (modified New York criteria), active (Bath AS Disease Activity Index (BASDAI) >/=40), severe (radiological intervertebral bridges) AS refractory to non-steroidal anti-inflammatory drugs and were antitumour necrosis factor naive. They were treated with ETN 50 mg once weekly or identical placebo (PBO). RESULTS: /st> Of the 95 patients screened, 82 were randomised to receive ETN (n=39) or PBO (n=43). At baseline the disease was active (mean BASDAI 61.0+/-13.4, C reactive protein (CRP) 20.7+/-25.5 mg/l) and severe (mean Bath AS Metrology Index (BASMI) 5.7+/-1.3, mSASSS 36.5+/-20.5); forced pulmonary vital capacity (FVC) was 3.3+/-0.7 l. Improvement in BASDAI (normalised net incremental area under the curve between baseline and week 12, primary end point) was significantly greater in the ETN group than in the PBO group (-19.8+/-16.5 vs -11.0+/-16.4, p=0.019). Moreover, at week 12, ETN gave better results than PBO for the BASDAI (-26.4+/-19.7 vs -14.4+/-19.7; p=0.008), total back pain (-29.2+/-24.0 vs -14.9+/-24.0; p=0.010), BASFI (-21.7+/-17.6 vs -10.1+/-17.6; p=0.004), BASMI (-0.6+/-0.6 vs -0.2+/-0.6; p=0.011), CRP level (-15.7+/-14.2 vs -1.3+/-14.2; p<0.001) and FVC (+160+/-280 ml vs -20+/-280 ml; p=0.006). CONCLUSIONS: /st> ETN has short-term efficacy for patients with advanced AS, as was previously reported for less advanced disease. The efficacy is observed for the main symptoms (pain) and on markers of inflammation (CRP), as well as disease severity in terms of spinal mobility and pulmonary function.
Tárgyszavak:Orvostudományok Klinikai orvostudományok idegen nyelvű folyóiratközlemény külföldi lapban
Megjelenés:Annals Of The Rheumatic Diseases 70 : 5 (2011), p. 799-804. -
További szerzők:Braun, Jurgen Szántó Sándor (1968-) (belgyógyász, reumatológus) Combe, Bernard Elbaz, M. Géher Pál Thabut, G. Leblanc, Véronique Logeart, Isabelle
Internet cím:Szerző által megadott URL
DOI
Intézményi repozitóriumban (DEA) tárolt változat
elektronikus elérés
Borító:
Rekordok letöltése1